Resource Logo

Phenylarsine oxide inhibits ex vivo HIV-1 expression.


Biomed Pharmacother. 1997;51(10):430-8. Unique Identifier : AIDSLINE

Phenylarsine oxide (PAO), which is described as an inhibitor of tyrosine phosphatase activity, inhibits H2O2 release from human peripheral blood mononuclear cells (PBMCs) as measured by electrochemistry. Since human immunodeficiency virus type 1 (HIV-1) replication is known to be favored under oxidative stress conditions, ex vivo experiments using uninfected PBMCs, primary monocytes or a latently infected promonocytic U1 cell line show that HIV-1 replication and reactivation, monitored by p24 antigen measurement, are inhibited by PAO in a time- and concentration-dependent manner. These observations can be linked with the inhibition of NF-kappa B activation when uninfected monocytes are induced by either tumor necrosis factor alpha (TNF-alpha) phorbol 12-myristate 13-acetate (PMA) or lipopolysaccharide (LPS).

JOURNAL ARTICLE Arsenicals/*PHARMACOLOGY Cell Line Enzyme Inhibitors/PHARMACOLOGY Human Hydrogen Peroxide/ANALYSIS HIV Core Protein p24/BIOSYNTHESIS HIV-1/*DRUG EFFECTS/PHYSIOLOGY Lipopolysaccharides/PHARMACOLOGY Monocytes/DRUG EFFECTS/*PHYSIOLOGY/*VIROLOGY NF-kappa B/METABOLISM Oxidative Stress Protein-Tyrosine-Phosphatase/ANTAGONISTS & INHIB Support, Non-U.S. Gov't Tetradecanoylphorbol Acetate/PHARMACOLOGY Tumor Necrosis Factor/PHARMACOLOGY Virus Replication/*DRUG EFFECTS


Information in this article was accurate in March 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.